HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Despite extensive research into diabetes–cancer connection, answers remain elusive
• IOM: US faces cancer care crisis
• FDA panel: CT colonography a viable colorectal cancer screening option
• FDA approves Abraxane for metastatic pancreatic cancer
• FDA to review dabigatran for indications for DVT, PE
• ODAC supports Perjeta approval for HER-2–positive breast cancer
• FDA grants priority review for Nexavar for treatment of thyroid cancer
• Hydroxyurea reduced medical costs for children with sickle cell anemia
• Majority of childhood cancer survivors likely to be fertile
• Psychosocial services underutilized by those with head and neck cancers
• Neoadjuvant regimen prolonged OS in late-stage nasopharyngeal cancer
• Early intervention prolonged time to progression in smoldering myeloma
• Pemetrexed maintenance therapy improved OS in NSCLC
• Adjuvant therapy has not improved survival in metastatic basal cell carcinoma
• Bevacizumab plus chemotherapy extends survival in HER-2–negative breast cancer
• Children with melanoma did not meet ABCDE detection criteria
• Finasteride linked to reduced prostate cancer risk, no effect on OS
• HR loss predicted lymph node metastasis, poor prognosis in endometrial cancer
• Imatinib discontinuation safe in CML patients with durable response
• IV iron therapy reduced need for transfusion, increased infection risk
• Low-risk thyroid cancers overtreated due to ‘epidemic in diagnosis’
• Menopausal symptoms more troublesome for cancer survivors
• Meta-analysis shows dietary fiber intake lowers risk for gastric cancer
• Patients with HER-2–positive breast cancer preferred subcutaneous trastuzumab to IV administration
• Persistent intestine damage increased lymphoma risk in patients with celiac disease
• RFA yields better outcomes than resection in elderly patients with early HCC
• Rituximab maintenance did not significantly extend PFS in follicular lymphoma
• Second-line pazopanib effective in advanced RCC
• Study: Older patients at increased risk of DVT after Achilles tendon rupture
• Melanoma drug Yervoy did not reach primary endpoint in prostate cancer study
• Expanded access study confirms Kadcyla safe, active in pretreated HER-2–positive breast cancer
• First-line everolimus plus exemestane prolonged PFS in advanced breast cancer
• Genetic variations influence everolimus benefit in advanced breast cancer
• Survival after CNS metastases varied by breast cancer subtype
• Regorafenib renews hope for patients with refractory advanced GIST Van A. Trinh, PharmD, BCOP; Jennifer Davis, PharmD, BCOP